Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
AGING
MCID: AGN016
MIFTS: 62

Aging (AGING)

Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Aging

About this section

MalaCards integrated aliases for Aging:

Name: Aging 57 76 3

External Ids:

OMIM 57 502000
Sources

Summaries for Aging

About this section
OMIM : 57 Progressive damage to mitochondrial DNA (mtDNA) during life is thought to contribute to aging processes. This notion is supported by the observation of an aging-related accumulation in human mtDNA of oxidative and alkylation derivatives of nucleotides, of small deletions and insertions, and of large deletions, although their low frequency raises questions about their functional significance (Michikawa et al., 1999). (502000)

MalaCards based summary : Aging is related to huntington disease and atypical werner syndrome. An important gene associated with Aging is BCYRN1 (Brain Cytoplasmic RNA 1), and among its related pathways/superpathways are Cellular Senescence (REACTOME) and Endometrial cancer. The drugs Acetylcholine and Metformin have been mentioned in the context of this disorder. Affiliated tissues include brain, skin and heart, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 76 Senescence (/sɪ�?n�?s�?ns/) or biological aging is the gradual deterioration of functional... more...

Sources

Related Diseases for Aging

About this section

Diseases related to Aging via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 3990)
# Related Disease Score Top Affiliating Genes
1 huntington disease 31.9 AKT1 PPARG SNCA SOD1 TP53
2 atypical werner syndrome 31.5 LMNA WRN
3 prostate disease 31.5 AKT1 PPARG TP53
4 leukemia, acute myeloid 31.4 AKT1 JUN PARP1 SNCA TP53
5 vascular disease 31.3 NAMPT PPARG SERPINE1 SOD1
6 breast disease 31.3 PARP1 PPARG SOD2 TP53
7 prostate cancer 31.2 AKT1 HIF1A JUN MMP7 PARP1 PDGFRB
8 adamantinoma of long bones 31.1 BCYRN1 HIF1A PARP1 TP53
9 esophageal cancer 30.9 AKT1 BCYRN1 HIF1A JUN MMP7 TP53
10 ovarian cancer 30.9 AKT1 BCYRN1 HIF1A JUN PARP1 TP53
11 colorectal cancer 30.6 AKT1 BCYRN1 HIF1A JUN MMP7 PARP1
12 diabetes mellitus 30.6 AKT1 NAMPT PPARG SERPINE1 SOD2 WRN
13 diabetes mellitus, noninsulin-dependent 30.1 AKT1 LMNA NAMPT PPARG SERPINE1 SIRT1
14 body mass index quantitative trait locus 11 30.0 AKT1 LMNA NAMPT PPARG SERPINE1
15 overnutrition 29.9 NAMPT PPARG SERPINE1
16 nasopharyngeal carcinoma 29.8 AKT1 HIF1A JUN PARP1 TP53
17 endometrial cancer 29.8 AKT1 HIF1A JUN MMP7 TP53
18 endometrial adenocarcinoma 29.7 AKT1 HIF1A TP53
19 glioblastoma multiforme 29.7 AKT1 HIF1A PDGFRB PPARG TP53
20 squamous cell carcinoma 29.6 AKT1 BCYRN1 MMP7 TP53 TP63
21 cervical cancer 29.6 AKT1 BCYRN1 HIF1A PARP1 TP53 TP63
22 glioblastoma 29.5 AKT1 BCYRN1 HIF1A PDGFRB PPARG TP53
23 ewing sarcoma 29.4 AKT1 HIF1A JUN PARP1 PDGFRB SERPINE1
24 nervous system disease 29.4 AKT1 SNCA SOD1 TP53
25 glucose metabolism disease 29.3 AKT1 PPARG SERPINE1
26 lung cancer 29.2 AKT1 BCYRN1 HIF1A JUN MMP7 PARP1
27 squamous cell carcinoma, head and neck 29.2 AKT1 HIF1A TP53 TP63
28 lung cancer susceptibility 3 29.1 AKT1 HIF1A JUN PARP1 TP53 TP63
29 macular degeneration, age-related, 1 12.6
30 neuropathy, hereditary, with or without age-related macular degeneration 12.4
31 macular degeneration, age-related, 12 12.3
32 macular degeneration, age-related, 10 12.3
33 age-related hearing loss 12.3
34 premature aging syndrome, penttinen type 12.3
35 macular degeneration, age-related, 2 12.3
36 macular degeneration, age-related, 5 12.3
37 macular degeneration, age-related, 13 12.3
38 macular degeneration, age-related, 7 12.3
39 macular degeneration, age-related, 8 12.2
40 macular degeneration, age-related, 4 12.2
41 macular degeneration, age-related, 9 12.2
42 macular degeneration, age-related, 11 12.2
43 macular degeneration, age-related, 6 12.2
44 macular degeneration, age-related, 14 12.2
45 macular degeneration, age-related, 15 12.2
46 age-related hearing impairment 1 12.2
47 age-related hearing impairment 2 12.1
48 cataract, age-related nuclear 12.1
49 short stature and advanced bone age, with or without early-onset osteoarthritis and/or osteochondritis dissecans 12.1
50 menarche, age at, quantitative trait locus 1 12.0

Graphical network of the top 20 diseases related to Aging:



Diseases related to Aging
Sources

Symptoms & Phenotypes for Aging

About this section

Clinical features from OMIM:

502000

GenomeRNAi Phenotypes related to Aging according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00221-A-1 10.2 AKT1 PDGFRB PPARG
2 Decreased viability GR00221-A-2 10.2 AKT1 JUN PPARG SOD1
3 Decreased viability GR00221-A-3 10.2 AKT1 JUN PDGFRB PPARG SOD1
4 Decreased viability GR00221-A-4 10.2 AKT1 PDGFRB PPARG SOD1
5 Decreased viability GR00342-S-1 10.2 PDGFRB
6 Decreased viability GR00402-S-2 10.2 AKT1 JUN PDGFRB PPARG SOD1
7 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.78 AKT1 HIF1A JUN SIRT1 SNCA SOD1
8 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.78 AKT1 HIF1A JUN SIRT1 SNCA SOD1
9 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-3 9.56 HIF1A JUN PARP1 SIRT1 SOD1 TP53

MGI Mouse Phenotypes related to Aging:

46 (show all 27)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.55 AKT1 HIF1A JUN KL LMNA MMP7
2 growth/size/body region MP:0005378 10.54 AKT1 HIF1A JUN KL LMNA MMP7
3 cellular MP:0005384 10.52 AKT1 HIF1A JUN KL LMNA MMP7
4 homeostasis/metabolism MP:0005376 10.51 AKT1 HIF1A JUN KL LMNA MMP7
5 immune system MP:0005387 10.5 AKT1 HIF1A JUN KL LMNA MMP7
6 behavior/neurological MP:0005386 10.47 AKT1 HIF1A JUN KL LMNA PARP1
7 hematopoietic system MP:0005397 10.47 AKT1 HIF1A JUN KL LMNA MMP7
8 integument MP:0010771 10.47 AKT1 HIF1A JUN KL LMNA NAMPT
9 mortality/aging MP:0010768 10.45 AKT1 HIF1A JUN KL LMNA MMP7
10 endocrine/exocrine gland MP:0005379 10.44 AKT1 HIF1A JUN KL LMNA NAMPT
11 adipose tissue MP:0005375 10.33 AKT1 KL LMNA PDGFRB PPARG SERPINE1
12 digestive/alimentary MP:0005381 10.3 HIF1A KL LMNA MMP7 PDGFRB SIRT1
13 embryo MP:0005380 10.3 AKT1 HIF1A JUN NAMPT PARP1 PDGFRB
14 nervous system MP:0003631 10.28 AKT1 HIF1A JUN KL LMNA NAMPT
15 liver/biliary system MP:0005370 10.25 AKT1 HIF1A JUN KL LMNA PPARG
16 craniofacial MP:0005382 10.21 HIF1A KL LMNA PDGFRB SIRT1 TP53
17 neoplasm MP:0002006 10.2 AKT1 HIF1A MMP7 PPARG SERPINE1 SIRT1
18 hearing/vestibular/ear MP:0005377 10.18 KL LMNA PARP1 PPARG SIRT1 SOD1
19 muscle MP:0005369 10.18 AKT1 HIF1A KL LMNA PDGFRB PPARG
20 limbs/digits/tail MP:0005371 10.13 HIF1A KL LMNA PDGFRB SIRT1 TP53
21 renal/urinary system MP:0005367 10.1 HIF1A KL LMNA PARP1 PDGFRB PPARG
22 normal MP:0002873 10.07 AKT1 HIF1A JUN LMNA PDGFRB PPARG
23 reproductive system MP:0005389 10.07 AKT1 KL LMNA PARP1 PDGFRB PPARG
24 no phenotypic analysis MP:0003012 9.95 JUN PARP1 PPARG SIRT1 SNCA TP53
25 respiratory system MP:0005388 9.81 AKT1 HIF1A JUN KL LMNA SERPINE1
26 skeleton MP:0005390 9.77 AKT1 HIF1A JUN KL LMNA PDGFRB
27 vision/eye MP:0005391 9.47 HIF1A JUN KL LMNA MMP7 PARP1
Sources

Drugs & Therapeutics for Aging

About this section

Drugs for Aging (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 917)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetylcholine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-84-3 187
2
Metformin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 657-24-9 14219 4091
3
Dopamine Approved Phase 4,Phase 3,Phase 2,Not Applicable 51-61-6, 62-31-7 681
4
Methylphenidate Approved, Investigational Phase 4,Phase 3,Phase 2 113-45-1 4158
5
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 2,Phase 3 113775-47-6 68602 5311068
6
Propofol Approved, Investigational, Vet_approved Phase 4,Not Applicable 2078-54-8 4943
7
Digoxin Approved Phase 4 20830-75-5 30322 2724385
8
Clopidogrel Approved Phase 4,Phase 3 113665-84-2, 120202-66-6 60606
9
Ticlopidine Approved Phase 4,Phase 3 55142-85-3 5472
10
Pantoprazole Approved Phase 4 102625-70-7 4679
11
Aspirin Approved, Vet_approved Phase 4,Phase 3 50-78-2 2244
12
Rilpivirine Approved Phase 4 500287-72-9
13
Darunavir Approved Phase 4 206361-99-1, 635728-49-3 213039
14
Cobicistat Approved Phase 4 1004316-88-4
15
Hyaluronic acid Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 9004-61-9 53477741
16
Medroxyprogesterone acetate Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 71-58-9
17
Levobupivacaine Approved, Investigational Phase 4 27262-47-1 92253
18
Testosterone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 58-22-0 6013
19
Testosterone enanthate Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 315-37-7 9416
20
Methyltestosterone Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 58-18-4 6010
21
Testosterone undecanoate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 5949-44-0
22
Anastrozole Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 120511-73-1 2187
23
Donepezil Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 120014-06-4 3152
24 Orange Approved Phase 4,Phase 3,Not Applicable
25 Grape Approved Phase 4,Phase 2,Phase 1,Not Applicable
26
Lidocaine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Early Phase 1,Not Applicable 137-58-6 3676
27
Isoflurane Approved, Vet_approved Phase 4,Not Applicable 26675-46-7 3763
28
Sevoflurane Approved, Vet_approved Phase 4,Not Applicable 28523-86-6 5206
29
Ethanol Approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 64-17-5 702
30
Tocopherol Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1406-66-2 14986
31
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 94-09-7, 1994-09-7 2337
32 tannic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
33
Triamcinolone Approved, Vet_approved Phase 4,Phase 2,Not Applicable 124-94-7 31307
34
Ibuprofen Approved Phase 4,Phase 3,Phase 1,Not Applicable 15687-27-1 3672
35
Celecoxib Approved, Investigational Phase 4,Phase 3 169590-42-5 2662
36
Armodafinil Approved, Investigational Phase 4,Phase 2 112111-43-0
37
Modafinil Approved, Investigational Phase 4,Phase 2 68693-11-8 4236
38
Naproxen Approved, Vet_approved Phase 4,Phase 2,Phase 3 22204-53-1 1302 156391
39 Estradiol valerate Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 979-32-8
40
Polyestradiol phosphate Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 28014-46-2
41
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 50-28-2 5757
42
Morphine Approved, Investigational Phase 4,Not Applicable 57-27-2 5288826
43
Zinc Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 7440-66-6
44
Mannitol Approved, Investigational Phase 4,Phase 1,Phase 2,Not Applicable 69-65-8 453 6251
45
Emtricitabine Approved, Investigational Phase 4,Phase 2 143491-57-0 60877
46
Pectin Approved, Investigational, Vet_approved Phase 4,Not Applicable 9000-69-5 441476
47
Loperamide Approved Phase 4,Early Phase 1,Not Applicable 53179-11-6 3955
48
Citalopram Approved Phase 4,Phase 3,Not Applicable 59729-33-8 2771
49
Simvastatin Approved Phase 4,Phase 3,Phase 2 79902-63-9 54454
50
Pravastatin Approved Phase 4,Phase 3 81093-37-0 54687

Interventional clinical trials:

(show top 50) (show all 3589)
# Name Status NCT ID Phase Drugs
1 Comparison of Escalating Doses of IncobotulinumtoxinA (Xeomin®) in the Treatment of Glabellar Rhytids Unknown status NCT01583478 Phase 4
2 Effects of Omega-3 Fatty Acids on Bone and Frailty Unknown status NCT00634686 Phase 4
3 Metformin Induces a Dietary Restriction-like State in Human Unknown status NCT02745886 Phase 4 metformin 0.85 twice daily for 6 months
4 Ritalin, Memory and Attention in MCI: a Behaviour-EEG Study Unknown status NCT02326038 Phase 4 Methylphenidate
5 Rosuvastatin Effect on Telomere-telomerase System in ACS Unknown status NCT02299245 Phase 4 rosuvastatin
6 Postoperative Recovery in Elderly Patients Undergoing Hip Hemi-arthroplasty Unknown status NCT01934049 Phase 4 Total Intravenous Anesthesia and Peripheral nerve blocks
7 Marinobufagenin as a Target for DIGIBIND in Hypertensive Patients With End-stage Renal Disease Unknown status NCT00852787 Phase 4 Digoxin immune fab;Placebo
8 Does Early Re-administration of Aspirin/Clopidogrel Increase the Risk of Bleeding From Artificial Ulcer After EMR or ESD? Unknown status NCT01621451 Phase 4 aspirin and/or clopidogrel;aspirin and/or clopidogrel
9 Open Label, Pilot Study of Darunavir Boosted by Cobicistat in Combination With Rilpivirine to Treat HIV+ Naïve Subjects Unknown status NCT02404233 Phase 4 darunavir/cobicistat;rilpivirine
10 Frailty and Cognitive Function Assessment of TAVI Patients Unknown status NCT02650388 Phase 4
11 Mindfulness-Based Cognitive Therapy for Depression and Anxiety Unknown status NCT02777905 Phase 4
12 The Effect of a Higher Dose of Dehydroepiandrosterone (DHEA) Supplementation in Poor Responders Unknown status NCT02357472 Phase 4 dehydroepiandrosterone
13 The Impact of Hyaluronic Acid Injections on Osteoarthritic Knee Mechanics Unknown status NCT00778076 Phase 4
14 The Effects of Blood Pressure Reduction on Cerebral Perfusion and Cognition in the Elderly Population Unknown status NCT00966199 Phase 4 anti-hypertensive medication
15 Herbal Alternatives for Menopause Symptoms (HALT Study) Unknown status NCT00169299 Phase 4 Black cohosh;Multibotanical preparation;Multibotanical preparation + dietary soy counseling;Conjugated equine estrogen +/- medroxyprogesterone acetate
16 A Dose Finding Study for Pain Relief of a Broken Hip Unknown status NCT00926666 Phase 4 Levobupivacaine
17 Testosterone Replacement in Middle-Aged Hypogonadal Men With Dysthymia: Parallel Group, Double Blind Randomized Trial Unknown status NCT00260390 Phase 4 Testoviron
18 Aromatase Inhibitors and Weight Loss in Severely Obese Hypogonadal Male Veterans (Pilot) Unknown status NCT02959853 Phase 4 Anastrazole
19 Clinical Trial to Evaluate the Efficacy of FITOGYN Versus Placebo on the Vasomotor Symptomatology Associated With Menopause Unknown status NCT01116310 Phase 4 Soy isoflavones (Glycine max L) and red clover extract (Trifolium pretense L);Placebo
20 CALM-AD Unknown status NCT00142324 Phase 4 Donepezil
21 Retinol on Human Skin Aging in East Asian Descent Completed NCT02906566 Phase 4 Retinol;Placebo
22 Volume Restoration of the Aging Midface With Sculptra Aesthetic Completed NCT01307865 Phase 4 injectable poly-L-lactic acid
23 Changing in Skin Physiology After Microdroplet Placement of Stabilized Hyaluronic Acid in Aging Faces Completed NCT02312154 Phase 4
24 Study of the Effect of Atorvastatin for Reducing Aging-related Complication in HIV-infected Patients Older Than 45 Years Receiving a Protease Inhibitor-based Regimen Versus a Raltegravir-based Regimen Completed NCT02577042 Phase 4 Raltegravir;PI-based regimen;Atorvastatin
25 Pectin, Aging and Intestinal Barrier Function Completed NCT02376270 Phase 4
26 Brain Imaging and Mental Disorders of Aging Intervention Completed NCT00267163 Phase 4 donepezil;Placebo
27 PPV: Pneumococcal Polysaccharide Vaccine in Older Adults Completed NCT00239694 Phase 4
28 Canadian Aesthetic Experience With Sculptra Therapy Completed NCT00447551 Phase 4 Poly-L-Lactic Acid
29 Metformin in Longevity Study (MILES). Completed NCT02432287 Phase 4 Metformin;Placebo
30 Aging Brain Changes, Executive Dysfunction and Depression Completed NCT00918684 Phase 4 Escitalopram
31 Memory and Mental Health in Aging Completed NCT02988908 Phase 4 Donepezil;Placebos
32 Testosterone Effects on Bone and Frailty Completed NCT00182871 Phase 4 testosterone
33 The Effect of Luteinizing Hormone (LH) Supplementation Following Gonadotropin-releasing Hormone (GnRH) Antagonist Administration in Advanced Reproductive Ageing Women Undergoing IVF and Embryo Transfer (IVF/ET) Completed NCT01016210 Phase 4 Leuveris;Leuveris
34 Clinical Evaluation of Day and Night Skin Care Creams Supplemented With MediCell Technology (MCT)'s Composition of Defensins and Supportive Molecules Completed NCT02765763 Phase 4 2-Minute Reveal Masque;24/7 Barrier Repair Cream;8-in-1 BioSerum;Null Formula 2-Minute Reveal Masque;Null Formula 24/7 Barrier Repair Cream;Null Formula 8-in-1 BioSerum
35 Effect of a Transcutaneous Electrical Nerve Stimulation (TENS) Device on Overall Facial Appearance Completed NCT01740440 Phase 4
36 Comparative Study of the Effect of Dysport and Botox Completed NCT00434863 Phase 4 botulinum toxin type A
37 Poly-L-lactic Acid for Skin Quality Completed NCT02003833 Phase 4
38 Effects of a Proprietary Blend of Herbal Extract Supplement on Cellular Detoxification, Inflammation, and Cumulative Cognitive Index as Well as Gene Expression in Middle-Aged Adult Women Completed NCT01598272 Phase 4
39 Comparison of Outcome Parameters in Laser Rhytide Treatment Completed NCT00994474 Phase 4
40 Patient Satisfaction With Treatment of BOTOX® Cosmetic for the Temporary Correction of Moderate to Severe Glabellar Lines Completed NCT00856414 Phase 4
41 Comparative Study of Reconstituted JUVÉDERM® Ultra vs COSMODERM® 1 for Lip and Cheek Lines, Folds or Wrinkles Completed NCT01212809 Phase 4
42 Efficacy of Fenugreek Seed and Lespedeza Cuneata in TDS Completed NCT03057899 Phase 4 TFG capsules (200 mg /capsule);Placebo oral capsule
43 Metformin and Longevity Genes in Prediabetes Completed NCT01765946 Phase 4 Metformin;placebo
44 Do HMG CoA Reductase Inhibitors Affect Abeta Levels? Completed NCT00303277 Phase 4 simvastatin;pravastatin
45 Optimizing Body Composition for Function in Older Adults Completed NCT00315146 Phase 4 Pioglitazone;Placebo
46 Effect of Revival Soy on Weight Loss and Skin, Hair, and Nails in Premenopausal Women Completed NCT00352157 Phase 4
47 Onabotulinum Toxin Type A and Abobotulinum Toxin Type A Crow's Feet Rhytid Study Completed NCT01529788 Phase 4 Right lateral orbital injection of Botox Cosmetic or Dysport;Left lateral orbital injection of Botox Cosmetic or Dysport
48 Study to Assess DerMend Moisturizing Bruise Formula in Improving the Appearance of Chronically Aged Forearms and Hands Completed NCT01910831 Phase 4 DerMend Moisturizing Bruise Formula
49 Anabolic and Inflammatory Responses to Short-Term Testosterone Administration in Older Men Completed NCT00957801 Phase 4 Testosterone injection;Testosterone gel;Medrol
50 Zurich Multiple Endpoint Vitamin D Trial in Knee OA Patients Completed NCT00599807 Phase 4

Search NIH Clinical Center for Aging

Sources

Genetic Tests for Aging

About this section
Sources

Anatomical Context for Aging

About this section

MalaCards organs/tissues related to Aging:

41
Brain, Skin, Heart, Bone, Skeletal Muscle, Breast, Prostate
Sources

Publications for Aging

About this section

Articles related to Aging:

(show top 50) (show all 4500)
# Title Authors Year
1
Essential oils and functional herbs for healthy aging. ( 30539810 )
2019
2
The Academic Health Department: Aging Gracefully? ( 30507803 )
2019
3
Aging gracefully: social engagement joins exercise and enrichment as a key lifestyle factor in resistance to age-related cognitive decline. ( 30531067 )
2019
4
Epigenetic silencing of Lgr5 induces senescence of intestinal epithelial organoids during the process of aging. ( 30534415 )
2019
5
MMP-3 and MMP-8 in rat mandibular condylar cartilage associated with dietary loading, estrogen level, and aging. ( 30412863 )
2019
6
Sarcopenia: Aging-Related Loss of Muscle Mass and Function. ( 30427277 )
2019
7
Effects of estrogen and aging on synaptic morphology and distribution of phosphorylated Tyr1472 NR2B in the female rat hippocampus. ( 30384123 )
2019
8
Enhanced Cu and Cd sorption after soil aging of woodchip-derived biochar: What were the driving factors? ( 30384316 )
2019
9
Investigating proximity of crash locations to aging pedestrian residences. ( 30390517 )
2019
10
Intrinsic neurocognitive network connectivity differences between normal aging and mild cognitive impairment are associated with cognitive status and age. ( 30391818 )
2019
11
A principled multivariate intersubject analysis of generalized partial directed coherence with Dirichlet regression: Application to healthy aging in areas exhibiting cortical thinning. ( 30392951 )
2019
12
Genetic predisposition for inflammation exacerbates effects of striatal iron content on cognitive switching ability in healthy aging. ( 30395929 )
2019
13
Relative Volta Potentials of Intermetallics in AZ91-RE Mg Alloy After Solution and Aging Treatment. ( 30327021 )
2019
14
The Lifespan Human Connectome Project in Aging: An overview. ( 30332613 )
2019
15
Dendritic spine remodeling accompanies Alzheimer's disease pathology and genetic susceptibility in cognitively normal aging. ( 30339964 )
2019
16
Anti-oxidation and anti-aging activity of polysaccharide from Malus micromalus Makino fruit wine. ( 30342941 )
2019
17
Upscaling fixed bed adsorption behaviors towards emerging micropollutants in treated natural waters with aging activated carbon: Model development and validation. ( 30343196 )
2019
18
Effects of aging, high-fat diet, and testosterone treatment on neural and metabolic outcomes in male brown Norway rats. ( 30359877 )
2019
19
Spermidine: a physiological autophagy inducer acting as an anti-aging vitamin in humans? ( 30306826 )
2019
20
Aging alters envelope representations of speech-like sounds in the inferior colliculus. ( 30316050 )
2019
21
Decreased cingulo-opercular network functional connectivity mediates the impact of aging on visual processing speed. ( 30317033 )
2019
22
A 3D population-based brain atlas of the mouse lemur primate with examples of applications in aging studies and comparative anatomy. ( 30326295 )
2019
23
Transcriptomics and metabonomics of the anti-aging properties of total flavones of Epimedium in relation to lipid metabolism. ( 30278205 )
2019
24
Modification of Descending Analgesia in Aging: Critical Role of the Prefrontal Cortex. ( 30222616 )
2019
25
Phase transition and hardness evolution of a Ti-5Al-5Mo-1Fe-1Cr alloy subjected to isothermal aging. ( 30223177 )
2019
26
Daidzein upregulates anti-aging protein Klotho and NaPi 2a cotransporter in a rat model of the andropause. ( 30240906 )
2019
27
Melatonin as Potential Targets for Delaying Ovarian Aging. ( 30156157 )
2019
28
Do the physiological aging of the placenta and the changes in angiogenesis marker sFlt-1 and PlGF concentrations predispose patients to late-onset preeclampsia? ( 28816071 )
2019
29
HIV infection across aging: Synergistic effects on intrinsic functional connectivity of the brain. ( 29906495 )
2019
30
The Enzymatic Core of the Parkinson's Disease-Associated Protein LRRK2 Impairs Mitochondrial Biogenesis in Aging Yeast. ( 29977190 )
2018
31
Microglia and Aging: The Role of the TREM2-DAP12 and CX3CL1-CX3CR1 Axes. ( 29361745 )
2018
32
A parthenogenetic quasi-program causes teratoma-like tumors during aging in wild-type <i>C. elegans</i>. ( 29928508 )
2018
33
Aging effects on symbolic number comparison: No deceleration of numerical information retrieval but more conservative decision-making. ( 29975082 )
2018
34
Vitamin B12 deficiency and impaired expression of amnionless during aging. ( 29159972 )
2018
35
Effects of Aging on Transformation of Biogenic Magnetite Nanoparticles. ( 29448600 )
2018
36
The aging brain and cerebrovascular reactivity. ( 29981482 )
2018
37
NAD<sup>+</sup>Deficiency Is a Common Central Pathological Factor of a Number of Diseases and Aging: Mechanisms and Therapeutic Implications. ( 29295624 )
2018
38
Changes in neurofilament 200 and tyrosine hydroxylase expression in the cardiac innervation of diabetic rats during aging. ( 29175663 )
2018
39
Combined QTL mapping, physiological and transcriptomic analyses to identify candidate genes involved in Brassica napus seed aging. ( 29974306 )
2018
40
Effects of Mg Addition with Natural Aging Time on Two-Step Aging Behavior in Al-Mg-Si Alloys. ( 29448743 )
2018
41
Fecal peritonitis in aging rat model. Therapeutic response to different antibiotic strategies. ( 29924208 )
2018
42
Effect of chemical disinfectants and accelerated aging on maxillofacial silicone elastomers: An<i>In vitro</i>Study. ( 29442090 )
2018
43
Healthy brain aging: interplay between reactive species, inflammation and energy supply. ( 29452266 )
2018
44
Aging, Frailty, and Resilience. ( 29975391 )
2018
45
The curvilinear relationship of early-life adversity and successful aging: the mediating role of mental health. ( 29447460 )
2018
46
Apolipoprotein E genotype does not moderate the associations of depressive symptoms, neuroticism and allostatic load with cognitive ability and cognitive aging in the Lothian Birth Cohort 1936. ( 29451880 )
2018
47
The Role of Aging, Drug Dependence, and Hepatitis C Comorbidity in Alcoholism Cortical Compromise. ( 29541774 )
2018
48
Granzyme A in Human Platelets Regulates the Synthesis of Proinflammatory Cytokines by Monocytes in Aging. ( 29167233 )
2018
49
Current management of pelvic organ prolapse in aging women. ( 29444759 )
2018
50
Mito-micea88 and mitochondrial DNA mutator mice as models of human osteoporosis caused not by aging but by hyperparathyroidism. ( 29973435 )
2018
Sources

Variations for Aging

About this section
Sources

Expression for Aging

About this section
Search GEO for disease gene expression data for Aging.
Sources

Pathways for Aging

About this section

Pathways related to Aging according to GeneCards Suite gene sharing:

(show top 50) (show all 55)
# Super pathways Score Top Affiliating Genes
1
Cellular Senescence (REACTOME) 66
Show member pathways
 13.12 HIF1A JUN SIRT1 SOD1 SOD2 TP53
2
Endometrial cancer 37
Show member pathways
 12.86 AKT1 JUN PDGFRB PPARG TP53
3
Pathways in cancer 37
12.72 AKT1 HIF1A JUN PDGFRB PPARG TP53
4
Apoptosis Modulation and Signaling 1
Show member pathways
 12.67 AKT1 JUN LMNA PARP1 TP53 TP63
5
4-1BB Pathway 64
Show member pathways
 12.64 AKT1 JUN PDGFRB SIRT1 TP53
6
ErbB signaling pathway 1 37
Show member pathways
 12.47 AKT1 HIF1A JUN TP53
7
Glucose / Energy Metabolism 4
12.44 AKT1 NAMPT PPARG SIRT1 SOD2
8
AMP-activated Protein Kinase (AMPK) Signaling 1
Show member pathways
 12.42 AKT1 PPARG SIRT1 TP53
9
Apoptosis Pathway 72
Show member pathways
 12.42 AKT1 JUN PDGFRB TP53
10
WNT Signaling 64
12.41 AKT1 JUN MMP7 TP53
11
Human T-cell leukemia virus 1 infection 37
12.4 AKT1 JUN PDGFRB TP53
12
Phospholipase D signaling pathway 37
Show member pathways
 12.37 AKT1 HIF1A JUN PDGFRB
13
Selenium Micronutrient Network 1
Show member pathways
 12.3 SERPINE1 SOD1 SOD2 TP53
14
Apoptosis and survival Caspase cascade 22
Show member pathways
 12.23 AKT1 JUN LMNA PARP1
15
MAPK Signaling: Mitogen Stimulation Pathway 65
Show member pathways
 12.19 AKT1 LMNA PDGFRB TP53
16
p53 Signaling 64
Show member pathways
 12.19 AKT1 HIF1A SIRT1 TP53
17
BMAL1-CLOCK,NPAS2 activates circadian gene expression 66
Show member pathways
 12.17 HIF1A NAMPT SERPINE1 SIRT1
18
Cellular senescence (KEGG) 37
12.1 AKT1 SERPINE1 SIRT1 TP53
19
AKT Signaling Pathway 67
12.09 AKT1 LMNA PDGFRB TP53
20
mTOR Pathway 72
Show member pathways
 12.09 AKT1 JUN PPARG TP53
21
Integrated Breast Cancer Pathway 1
12.06 AKT1 JUN SIRT1 TP53
22
G-protein signaling Ras family GTPases in kinase cascades (scheme) 22
Show member pathways
 12.05 AKT1 HIF1A JUN PPARG SERPINE1 TP53
24
UVA-Induced MAPK Signaling 64
Show member pathways
 11.97 AKT1 JUN PARP1 TP53
25
Direct p53 effectors 1
11.96 JUN SERPINE1 TP53 TP63
26
Adipogenesis 1
11.89 HIF1A LMNA NAMPT PPARG SERPINE1
27
TGF-beta Signaling Pathways 65
11.87 AKT1 JUN PPARG
28
DNA Damage Response (only ATM dependent) 1
11.87 AKT1 JUN SOD2 TP53
29
Androgen receptor signaling pathway 1
11.84 AKT1 JUN SIRT1
30
Angiogenesis (CST) 4
11.83 HIF1A MMP7 PDGFRB
31
TP53 Regulates Metabolic Genes 66
11.79 AKT1 TP53 TP63
32
Glucocorticoid receptor regulatory network 1
11.77 AKT1 JUN TP53
33
VEGF Pathway (Tocris) 61
Show member pathways
 11.77 AKT1 JUN PDGFRB
34
Regulation of nuclear SMAD2/3 signaling 1
11.74 AKT1 JUN SERPINE1
35
Sterol Regulatory Element-Binding Proteins (SREBP) signalling 1
11.71 AKT1 PPARG SIRT1
36
Longevity regulating pathway 37
Show member pathways
 11.68 AKT1 KL PPARG SIRT1 SOD1 SOD2
37
Association Between Physico-Chemical Features and Toxicity Associated Pathways 1
11.67 AKT1 JUN SOD1
38
p75(NTR)-mediated signaling 1
Show member pathways
 11.65 AKT1 MMP7 TP53
39
Regulation of Telomerase 1
11.65 AKT1 JUN WRN
40
Mitophagy - animal 37
11.64 HIF1A JUN TP53
41
Central carbon metabolism in cancer 37
11.59 AKT1 HIF1A PDGFRB TP53
42
Regulation of retinoblastoma protein 1
11.57 JUN PPARG SIRT1
43
HIF-1-alpha transcription factor network 1
11.57 AKT1 HIF1A JUN SERPINE1
44
HIF1Alpha Pathway 64
11.54 HIF1A JUN TP53
45
PDGFR-beta signaling pathway 1
11.54 AKT1 HIF1A PDGFRB
46
Proteolysis Putative SUMO-1 pathway 22
Show member pathways
 11.53 AKT1 JUN TP53
47
Copper homeostasis 1
11.47 AKT1 JUN SOD1 TP53
48
FoxO family signaling 1
11.46 AKT1 SIRT1 SOD2
49
Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimers disease models 66
Show member pathways
 11.43 JUN LMNA SOD2
50
Hepatitis C and Hepatocellular Carcinoma 1
11.41 AKT1 HIF1A JUN TP53
Sources

GO Terms for Aging

About this section

Cellular components related to Aging according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mitochondrion GO:0005739 9.76 AKT1 PARP1 SIRT1 SNCA SOD1 SOD2
2 nucleoplasm GO:0005654 9.7 AKT1 HIF1A JUN LMNA PARP1 PPARG
3 nuclear chromatin GO:0000790 9.56 JUN SIRT1 TP53 TP63
4 protein-containing complex GO:0032991 9.17 AKT1 HIF1A PARP1 PPARG SOD1 TP53
5 nucleus GO:0005634 10.17 AKT1 HIF1A JUN LMNA NAMPT PARP1

Biological processes related to Aging according to GeneCards Suite gene sharing:

(show top 50) (show all 52)
# Name GO ID Score Top Affiliating Genes
1 angiogenesis GO:0001525 9.99 HIF1A JUN SERPINE1 SIRT1
2 regulation of apoptotic process GO:0042981 9.98 AKT1 SIRT1 TP53 TP63 WRN
3 positive regulation of transcription by RNA polymerase II GO:0045944 9.96 AKT1 HIF1A JUN NAMPT PARP1 PPARG
4 response to organic cyclic compound GO:0014070 9.92 JUN NAMPT PDGFRB PPARG
5 negative regulation of apoptotic process GO:0043066 9.92 AKT1 HIF1A JUN PDGFRB SIRT1 SNCA
6 response to oxidative stress GO:0006979 9.91 AKT1 SIRT1 SOD1 WRN
7 rhythmic process GO:0048511 9.9 NAMPT PPARG SIRT1 TP53
8 cellular response to insulin stimulus GO:0032869 9.89 AKT1 PARP1 PPARG
9 insulin receptor signaling pathway GO:0008286 9.87 AKT1 KL NAMPT
10 regulation of signal transduction by p53 class mediator GO:1901796 9.87 AKT1 TP53 TP63
11 protein homotetramerization GO:0051289 9.86 SOD2 TP53 TP63
12 regulation of blood pressure GO:0008217 9.85 PPARG SOD1 SOD2
13 response to organic substance GO:0010033 9.85 AKT1 JUN PPARG SOD1
14 circadian rhythm GO:0007623 9.84 JUN NAMPT SERPINE1 SIRT1
15 negative regulation of neuron death GO:1901215 9.83 AKT1 SIRT1 SNCA
16 cellular response to oxidative stress GO:0034599 9.83 PARP1 SNCA SOD1 SOD2
17 positive regulation of blood vessel endothelial cell migration GO:0043536 9.82 AKT1 HIF1A SIRT1
18 cellular response to cadmium ion GO:0071276 9.8 AKT1 JUN SOD1
19 positive regulation of endothelial cell proliferation GO:0001938 9.8 AKT1 HIF1A JUN SIRT1
20 negative regulation of neuron apoptotic process GO:0043524 9.8 HIF1A JUN SNCA SOD1 SOD2
21 cellular response to ionizing radiation GO:0071479 9.77 NAMPT SIRT1 TP53
22 cellular response to hypoxia GO:0071456 9.77 AKT1 HIF1A LMNA SIRT1 TP53
23 positive regulation of smooth muscle cell proliferation GO:0048661 9.76 AKT1 JUN NAMPT PDGFRB
24 positive regulation of apoptotic process GO:0043065 9.76 AKT1 JUN PDGFRB PPARG SIRT1 SNCA
25 intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator GO:0042771 9.74 SIRT1 TP53 TP63
26 positive regulation of pri-miRNA transcription by RNA polymerase II GO:1902895 9.73 HIF1A JUN TP53
27 response to hydrogen peroxide GO:0042542 9.73 JUN PDGFRB SIRT1 SOD1
28 removal of superoxide radicals GO:0019430 9.71 SOD1 SOD2
29 replicative senescence GO:0090399 9.71 SERPINE1 TP53
30 white fat cell differentiation GO:0050872 9.7 PPARG SIRT1
31 positive regulation of vascular associated smooth muscle cell apoptotic process GO:1905461 9.7 PPARG SOD2
32 DNA synthesis involved in DNA repair GO:0000731 9.7 SIRT1 WRN
33 negative regulation of telomerase activity GO:0051974 9.69 PPARG TP53
34 microglial cell activation GO:0001774 9.69 JUN NAMPT SNCA
35 response to fluid shear stress GO:0034405 9.68 AKT1 PDGFRB
36 retina vasculature development in camera-type eye GO:0061298 9.68 HIF1A PDGFRB
37 oxygen homeostasis GO:0032364 9.67 HIF1A SOD2
38 peripheral nervous system myelin maintenance GO:0032287 9.66 AKT1 SOD1
39 response to superoxide GO:0000303 9.65 SOD1 SOD2
40 negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathway GO:1902176 9.65 AKT1 SIRT1 SOD2
41 replicative cell aging GO:0001302 9.64 TP63 WRN
42 negative regulation of helicase activity GO:0051097 9.61 SIRT1 TP53
43 aging GO:0007568 9.36 AKT1 JUN KL MMP7 NAMPT PDGFRB
44 cell aging GO:0007569 9.35 SIRT1 SOD1 TP53 TP63 WRN
45 cell differentiation GO:0030154 10.17 AKT1 HIF1A PDGFRB PPARG SIRT1 TP53
46 apoptotic process GO:0006915 10.13 AKT1 PARP1 SIRT1 SNCA TP53 TP63
47 negative regulation of transcription by RNA polymerase II GO:0000122 10.12 JUN PARP1 PPARG SIRT1 SNCA TP53
48 positive regulation of cell proliferation GO:0008284 10.11 AKT1 JUN NAMPT PDGFRB SIRT1
49 positive regulation of transcription, DNA-templated GO:0045893 10.11 AKT1 HIF1A JUN PPARG TP53 TP63
50 transcription by RNA polymerase II GO:0006366 10.11 HIF1A JUN PARP1 SIRT1 TP53 TP63

Molecular functions related to Aging according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 zinc ion binding GO:0008270 9.97 MMP7 PARP1 PPARG SNCA SOD1 TP53
2 protein kinase binding GO:0019901 9.88 AKT1 HIF1A PARP1 PDGFRB TP53
3 chromatin binding GO:0003682 9.85 JUN PPARG TP53 TP63 WRN
4 protein domain specific binding GO:0019904 9.81 HIF1A SIRT1 SNCA TP63
5 transcription factor binding GO:0008134 9.73 HIF1A JUN PARP1 PPARG SIRT1 TP53
6 transcription regulatory region DNA binding GO:0044212 9.72 JUN PPARG SNCA TP53 TP63
7 DNA-binding transcription activator activity, RNA polymerase II-specific GO:0001228 9.71 HIF1A JUN PARP1 TP53
8 identical protein binding GO:0042802 9.7 AKT1 JUN NAMPT PARP1 PPARG SIRT1
9 copper ion binding GO:0005507 9.61 SNCA SOD1 TP53
10 p53 binding GO:0002039 9.46 HIF1A SIRT1 TP53 TP63
11 superoxide dismutase activity GO:0004784 9.37 SOD1 SOD2
12 enzyme binding GO:0019899 9.32 AKT1 HIF1A JUN PARP1 PDGFRB PPARG
Sources

Sources for Aging

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....